Outlook Therapeutics prices 5 million direct offering at market under Nasdaq rules

Outlook Therapeutics prices 5 million direct offering at market under Nasdaq rules
Outlook Therapeutics pricing direct offering

Outlook Therapeutics has announced the pricing of a 5.0 million dollar registered direct offering that is priced at-the-market under Nasdaq rules.

The fundraising move aims to bolster the company’s capital position and support its ongoing operations. The offering is being conducted in accordance with Nasdaq at-the-market pricing regulations, which often reflect the current market value rather than a set discount. The capital raise and its execution strategy may affect the company’s liquidity profile and investment outlook. Further details regarding the use of proceeds and investor participation have not yet been disclosed.

Earlier, Outlook Therapeutics won an appeal following a formal dispute resolution process related to ONS-5010 LYTENAVA, advancing the product’s development progress. Details of the dispute resolution can be found in a previous report. The appeal outcome preceded the company’s current fundraising efforts.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.
Weekly Top Bonuses
up to $2,500
deposit bonus for all clients
CLAIM BONUS
Your capital is at risk.